Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E McGovern

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Clinical Cardiology|April 11, 2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinDonald B Hunninghake, Mark E McGovern, Michael Koren, et al.
International Journal of Epidemiology|December 13, 2016
Do gifts increase consent to home-based HIV testing? A difference-in-differences study in rural KwaZulu-Natal, South AfricaMark E McGovern, Kobus Herbst, Frank Tanser, et al.
Global Mental Health (Cambridge, England)|January 9, 2023
Levels of depression, anxiety, and psychological distress among Ugandan adults during the first wave of the COVID-19 pandemic: cross-sectional evidence from a mobile phone-based population surveyEmma Clarke-Deelder, Slawa Rokicki, Mark E McGovern, et al.
Economics and Human Biology|September 24, 2015
Education, gender, and state-level disparities in the health of older Indians: Evidence from biomarker dataJinkook Lee, Mark E McGovern, David E Bloom, et al.
Food and Nutrition Bulletin|October 17, 2022
Childhood Stunting and Wasting Following Independence in South SudanDaniel J Hoffman, Ismail Kassim, Biram Ndiaye, et al.
Atherosclerosis|January 24, 2007
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)James M McKenney, Peter H Jones, Harold E Bays, et al.
The American Journal of Cardiology|March 14, 2003
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Harold E Bays, Carlos A Dujovne, Mark E McGovern, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 28, 2019
Effects of Extended-Release Niacin on Quartile Lp-PLA<sub>2</sub> Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH TrialRadmila Lyubarova, John J Albers, Santica M Marcovina, et al.
American Heart Journal|April 27, 2020
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular diseaseWilliam E Boden, Michael G Miller, Ruth McBride, et al.
Antiviral Therapy|February 17, 2007
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Michael P Dubé, Julia W Wu, Judith A Aberg, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Cardiology|April 11, 2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatinDonald B Hunninghake, Mark E McGovern, Michael Koren, et al.
International Journal of Epidemiology|December 13, 2016
Do gifts increase consent to home-based HIV testing? A difference-in-differences study in rural KwaZulu-Natal, South AfricaMark E McGovern, Kobus Herbst, Frank Tanser, et al.
Global Mental Health (Cambridge, England)|January 9, 2023
Levels of depression, anxiety, and psychological distress among Ugandan adults during the first wave of the COVID-19 pandemic: cross-sectional evidence from a mobile phone-based population surveyEmma Clarke-Deelder, Slawa Rokicki, Mark E McGovern, et al.
Economics and Human Biology|September 24, 2015
Education, gender, and state-level disparities in the health of older Indians: Evidence from biomarker dataJinkook Lee, Mark E McGovern, David E Bloom, et al.
Food and Nutrition Bulletin|October 17, 2022
Childhood Stunting and Wasting Following Independence in South SudanDaniel J Hoffman, Ismail Kassim, Biram Ndiaye, et al.
Atherosclerosis|January 24, 2007
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)James M McKenney, Peter H Jones, Harold E Bays, et al.
The American Journal of Cardiology|March 14, 2003
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])Harold E Bays, Carlos A Dujovne, Mark E McGovern, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|May 28, 2019
Effects of Extended-Release Niacin on Quartile Lp-PLA<sub>2</sub> Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH TrialRadmila Lyubarova, John J Albers, Santica M Marcovina, et al.
American Heart Journal|April 27, 2020
Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular diseaseWilliam E Boden, Michael G Miller, Ruth McBride, et al.
Antiviral Therapy|February 17, 2007
Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148Michael P Dubé, Julia W Wu, Judith A Aberg, et al.
Pageof 5